Clinical Trial Update: Vandetanib Risk Minimisation Effectiveness

View source ↗

Summary

This update reports on the effectiveness of risk minimisation measures for vandetanib in medullary thyroid carcinoma, based on the completed clinical trial NCT0…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Medullary Thyroid Carcinoma

Drugs mentioned

• Vandetanib (vandetanib)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Medullary Thyroid Cancer | Status: COMPLETED